Citation Impact
Citing Papers
Cyclin D2–Cyclin-Dependent Kinase 4/6 Is Required for Efficient Proliferation and Tumorigenesis following Apc Loss
2010
Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences
2009 StandoutScience
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
2010
Activation of Hypoxia-Inducible Factor-1 in Bacillary Angiomatosis
2005
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
2009
Hallmarks of Cancer: The Next Generation
2011 Standout
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
2006
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
2012
CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis
2014
Kaposi sarcoma herpesvirus–induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma
2004
Rac1 Activity Is Required for the Activation of Hypoxia-inducible Factor 1
2001 StandoutNobel
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
Tetracyclines inhibit activated B cell function
2001
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
2012
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway
2014
Reprogramming of human somatic cells to pluripotency with defined factors
2007 StandoutNature
Choosing anticancer drug targets in the postgenomic era
1999 StandoutNobel
Imaging in the era of molecular oncology
2008 StandoutNature
Hypoxia and Inflammation
2011 Standout
Cancer Statistics, 2006
2006 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
2012
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Involvement of chemokine receptors in breast cancer metastasis
2001 StandoutNature
The Hedgehog and Wnt signalling pathways in cancer
2001 StandoutNature
Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes
2003
Ca2+/Calmodulin Kinase-dependent Activation of Hypoxia Inducible Factor 1 Transcriptional Activity in Cells Subjected to Intermittent Hypoxia
2004 StandoutNobel
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Hallmarks of Cancer
2000 Standout
The AID enzyme induces class switch recombination in fibroblasts
2002 StandoutNatureNobel
Kaposi's Sarcoma-associated Herpesvirus-encoded G Protein-coupled Receptor Activation of c-Jun Amino-terminal Kinase/Stress-activated Protein Kinase and Lyn Kinase Is Mediated by Related Adhesion Focal Tyrosine Kinase/Proline-rich Tyrosine Kinase 2
1999
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo
2005 StandoutNobel
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
2015 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
2002 StandoutNobel
Lymphangiogenesis in development and human disease
2005 StandoutNature
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
2013
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
2008
Targeting apoptosis in cancer therapy
2020 Standout
The microenvironment of the tumour–host interface
2001 StandoutNature
Cyclin D as a therapeutic target in cancer
2011
Extrafollicular antibody responses
2003
Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression
2012 StandoutNobel
Identification and expansion of human colon-cancer-initiating cells
2006 StandoutNature
Genetic events in the pathogenesis of multiple myeloma
2007
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
Pathogenesis and treatment of renal failure in multiple myeloma
2008
The CDK inhibitors in cancer research and therapy
2011
Kaposi's Sarcoma-associated Herpesvirus Activation of Vascular Endothelial Growth Factor Receptor 3 Alters Endothelial Function and Enhances Infection
2005
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
The molecular characterization and clinical management of multiple myeloma in the post-genome era
2009
FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity
2001 StandoutNobel
Creation of human tumour cells with defined genetic elements
1999 StandoutNature
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
2007 StandoutNature
The Translesion DNA Polymerase ζ Plays a Major Role in Ig and bcl-6 Somatic Hypermutation
2001
The cancer genome
2009 StandoutNature
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
2008 Standout
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002 StandoutNobel
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
2014
Oncogenic transformation and experimental models of human cancer
2007
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
2007 StandoutNobel
Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys
2005
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Genes and pathways downstream of telomerase in melanoma metastasis
2006 StandoutNobel
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
CXC chemokines in angiogenesis
2000
Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance
2001 StandoutNobel
The molecular classification of multiple myeloma
2006
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Ongoing In Vivo Immunoglobulin Class Switch DNA Recombination in Chronic Lymphocytic Leukemia B Cells
2002
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis
2002 StandoutNobel
The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha.
2000
A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation
2001 StandoutNobel
DNA Double-Strand Breaks
2002 StandoutNobel
Targeting CDK4 and CDK6: From Discovery to Therapy
2015
Hypoxic retinal Müller cells promote vascular permeability by HIF-1–dependent up-regulation of angiopoietin-like 4
2013 StandoutNobel
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
2007
Multiple Myeloma
2011 Standout
Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin
2005
Activation-induced Deaminase (AID)-directed Hypermutation in the Immunoglobulin Sμ Region
2002 StandoutNobel
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
2015
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
2003
G-protein-coupled Receptor (GPCR) Kinase Phosphorylation and β-Arrestin Recruitment Regulate the Constitutive Signaling Activity of the Human Cytomegalovirus US28 GPCR
2003 StandoutNobel
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
2005
Works of Scott Ely being referenced
A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6
2006
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
2014
CDK Inhibitor p18INK4c Is Required for the Generation of Functional Plasma Cells
2002
Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy
2007
Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus
1998 Nature
Induction of prolonged early G1arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1
2013
Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
2003
Targeting Cdk4/6 in combination therapy of chemoresistant multiple myeloma
2008
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4
2012
Engagement of CD153 (CD30 Ligand) by CD30+ T Cells Inhibits Class Switch DNA Recombination and Antibody Production in Human IgD+ IgM+ B Cells
2000
Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma
2005
CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy
2004
A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
2010
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma
2003
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
2004
Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization
2010
Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma
2008